Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European committee on antimicrobial susceptibility testing, against yeast isolates obtained in France in 2005-2006

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 778-781

  Dannaoui, E ^a,b   Lortholary, O ^a,b   Raoux, D ^a   Bougnoux, M E ^b   Galeazzi, G ^c   Lawrence, C ^d   Moissenet, D ^e   Poilane, I ^f   Hoinard, D ^a   Dromer, F ^a   Bouges Michel, Claire ^g   Dunand, Jean ^h   Bretagne, Stéphane ⁱ   Fauchet, Nathalie ^j   Forget, Elisabeth ^k   Botterel, Françoise ^l   Bonnal, Christine ^l   Eloy, Odile ^m   David, Marie Françoise ⁿ   Mihaila, Liliana ⁿ   Chachaty, Elisabeth ^o   Adam, Olivier ^o   Chochillon, Christian ^p   Paugam, André ^q   Baixench, Marie Thérèse ^q   Cornet, Muriel ^r   Escande, Marie Christine ^s   Challier, Svetlana ^t   Lavarde, Véronique ^u   Datry, Annick ^v   Laklache, Houria ^v   Lmimouni, Bader ^v   Brun, Sophie ^v   Poirot, Jean Louis ^w   Lacroix, Claire ^x   Develoux, Michel ^y   Bonacorsi, Stéphane ^z   more..

^a INSTITUT PASTEUR   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL LOUIS MOURIER   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e ARMAND TROUSSEAU HOSPITAL   (France)

^f HÔPITAL JEAN VERDIER   (France)

^g AVICENNE HOSPITAL   (France)

^h HÔPITAL AMBROISE PARÉ   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^k BEAUJON HOSPITAL   (France)

^l BICÊTRE HOSPITAL   (France)

^m CENTRE HOSPITALIER DE VERSAILLES   (France)

ⁿ HÔPITAL PAUL BROUSSE   (France)

^o INSTITUT GUSTAVE ROUSSY   (France)

^p BICHAT HOSPITAL   (France)

^q Hôpital Cochin

^r Hôpital de l'Hôtel Dieu

^s Curie ^*

^t HÔPITAL NECKER ENFANTS MALADES   (France)

^u HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^v PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^w HÔPITAL SAINT ANTOINE   (France)

^x SAINT LOUIS HOSPITAL   (France)

^y HÔPITAL TENON   (France)

^z Hôpital Robert Debré

more..

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; MICAFUNGIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASCOMYCETES; BASIDIOMYCETES; CANDIDA ALBICANS; CANDIDA FERMENTATI; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA HAEMULONII; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; EUCAST METHOD; FRANCE; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FRANCE; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS; MYCOSES; YEASTS;

EID: 38649104144     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01140-07     Document Type: Article

References (32)

1. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, I. M. Jensen, J. D. Knudsen, B. Lundgren, H. C. Schonheyder, and M. Tvede. 2005. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol. 43:4434-4440.
2. Bai, F. Y., H. Y. Liang, and J. H. Jia. 2000. Taxonomic relationships among the taxa in the Candida guilliermondii complex, as revealed by comparative electrophoretic karyotyping. Int. J. Syst. Evol. Microbiol. 50:417-422.
3. Baixench, M. T., N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, S. Ramires, C. Piketty, and E. Dannaoui. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
4. Barchiesi, F., E. Spreghini, S. Tomassetti, A. Delia Vittoria, D. Arzeni, E. Manso, and G. Scalise. 2006. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob. Agents Chemother. 50:2719-2727.
5. Bartizal, C., and F. C. Odds. 2003. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47:2100-2107.
6. Chryssanthou, E., and M. Cuenca-Estrella. 2002. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
7. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzon, and J. L. Rodriguez-Tudela. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921.
8. Cuenca-Estrella, M., D. Rodriguez, B. Almirante, J. Morgan, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, M. Salvado, D. W. Warnock, A. Pahissa, and J. L. Rodriguez-Tudela. 2005. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J. Antimicrob. Chemother. 55:194-199.
9. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
10. Deresinski, S. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36:1445-1457.
11. Donnelly, S. M., D. J. Sullivan, D. B. Shanley, and D. C. Coleman. 1999. Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology 145:1871-1882.
12. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
13. Fleck, R., A. Dietz, and H. Hof. 2007. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J. Antimicrob. Chemother. 59:767-771.
14. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.
15. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
16. Laverdiere, M., D. Hoban, C. Restieri, and F. Habel. 2002. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J. Antimicrob. Chemother. 50:119-123.
17. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
18. Marco, F., M. A. Pfaller, S. A. Messer, and R. N. Jones. 1998. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 32:33-37.
19. Messer, S. A., D. J. Diekema, L. Boyken, S. Tendolkar, R. J. Hollis, and M. A. Pfaller. 2006. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol. 44:324-326.
20. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49:767-769.
21. Odds, F. C., M. Motyl, R. Andrade, J. Bille, E. Canton, M. Cuenca-Estrella, A. Davidson, C. Durussel, D. Ellis, E. Foraker, A. W. Fothergill, M. A. Ghannoum, R. A. Giacobbe, M. Gobernado, R. Handke, M. Laverdiere, W. Lee-Yang, W. G. Merz, L. Ostrosky-Zeichner, J. Peman, S. Perea, J. R. Perfect, M. A. Pfaller, L. Proia, J. H. Rex, M. G. Rinaldi, J. L. Rodriguez-Tudela, W. A. Schell, C. Shields, D. A. Sutton, P. E. Verweij, and D. W. Warnock. 2004. Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J. Clin. Microbiol. 42:3475-3482.
22. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
23. Pai, M. P., A. L. Jones, and C. K. Mullen. 2007. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method. Diagn. Microbiol. Infect. Dis. 58:129-132.
24. Pappas, P. G. 2007. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-1405.
25. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44:3533-3538.
26. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.
27. Pfaller, M. A., D. J. Diekema, S. A. Messer, R. J. Hollis, and R. N. Jones. 2003. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob. Agents Chemother. 47:1068-1071.
28. Pfaller, M. A., R. N. Jones, G. V. Doern, A. C. Fluit, J. Verhoef, H. S. Sader, S. A. Messer, A. Houston, S. Coffman, R. J. Hollis, et al. 1999. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. Diagn. Microbiol. Infect. Dis. 35:19-25.
29. Rodríguez-Tudela, J. L., F. Barchiesi, J. Bille, E. Chryssanthou, M. Cuenca-Estrella, D. Denning, J. P. Donnelly, B. Dupont, W. Fegeler, C. Moore, M. Richardson, P. E. Verweij, et al. 2003. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin. Microbiol. Infect. 9:i-viii.
30. Takakura, S., N. Fujihara, T. Saito, T. Kudo, Y. Iinuma, and S. Ichiyama. 2004. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J. Antimicrob. Chemother. 53:283-289.
31. Tawara, S., F. Ikeda, K. Maki, Y. Morishita, K. Otomo, N. Teratani, T. Goto, M. Tomishima, H. Ohki, A. Yamada, K. Kawabata, H. Takasugi, K. Sakane, H. Tanaka, F. Matsumoto, and S. Kuwahara. 2000. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob. Agents Chemother. 44:57-62.
32. Tortorano, A. M., A. Prigitano, E. Biraghi, and M. A. Viviani. 2005. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. J. Antimicrob. Chemother. 56:777-779.